Highlight
The Prospective Cutaneous Lymphoma International Prognostic Index (CLIPI) enables precise risk stratification in advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS), diseases with otherwise poor survival outcomes. CLIPI integrates four independent prognostic factors—N3 lymph node status, age over 60, elevated serum lactate dehydrogenase (LDH), and large-cell transformation in skin—to classify patients into low-, intermediate-, and high-risk groups with distinct 5-year overall survival rates (63.3%, 44.7%, and 18.3%, respectively). This model surpasses traditional staging systems by better capturing heterogeneity and supporting optimal treatment decisions.
